echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Koren's hanging up! Take 15 heavy-weight varieties, 36 over-rated varieties bright eyes, 11 new class 1 drugs, 41 new products on the road

    Koren's hanging up! Take 15 heavy-weight varieties, 36 over-rated varieties bright eyes, 11 new class 1 drugs, 41 new products on the road

    • Last Update: 2021-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Entering 2021, The Colum Pharmaceuticals product line continues to be happy news, 2 injections have been evaluated, 4 injections were approved at that time.
    just past 2020, Colum Pharmaceuticals has had a lot of gains: 15 varieties have been approved, 11 injections have been evaluated, and 2 innovative drugs have been approved clinically.
    there are currently 36 varieties of Columbo (16 of which are the first), 13 of which are injectables.
    imitation drives innovation, the company's 41 newly registered generic drugs in the review, 19 varieties sprint first imitation, 11 new class 1 drugs are in the clinical stage, is expected to be declared in 2021 5-6 NEW IND, KL-A167 injection (PD-L1) submitted to the NDA.
    4 new products to be approved! Take 15 heavyweight varieties Of Colum Pharmaceuticals in the approval of varieties Source: MED2.0 China Drug Review Database Minet data show that Colum Pharmaceuticals' omega-3 fish oil / long-chain fat milk injection, fluorine ratio The registration status of four varieties, such as lovine injection, compound amino acid (15AA-I.)/glucose electrolyte injection and converted sugar injection, has been changed to "in approval" and is expected to be approved for listing in the near past.
    4 varieties are injections, of which 3 varieties are reported according to the new classification, approved will be treated as a review, compound amino acids (15AA-I.)/glucose electrolyte injection is expected to become the first imitation in China, omega-3 fish oil / long-chain fat emulsion sprint domestic second home, fluorobilofen injection sprint domestic third home.
    it is worth mentioning that compound amino acids (15AA-I.)/glucose electrolyte injections, omega-3 fish oil/long-chain fat milk injections are intestinal nutrients.
    , colum's drug has been approved for eight out-of-intestinal nutrition drugs, including three-cavity bags, two-chamber bags and single-bag products.
    if approved, these two products will further enhance the market competitiveness of Colum Pharmaceuticals in the field of intestinal nutrition.
    that in 2020, the Colum Pharmaceuticals product line has been very fruitful.
    meters of intranet data show that in 2020 Colum Pharmaceuticals won a total of 15 generic drugs (24 regulations), of which 12 varieties with a new registered classification was approved, as if through the consistency evaluation.
    Hydrochloric acid valdina non-slice, compound amino acid (16AA-II.) / glucose (48%) electrolyte injection for the domestic first imitation
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.